Gregory A. Morris is a partner in the Intellectual Property (IP) and Patent Law Groups in New York. He has more than two decades of experience across the full spectrum of IP matters, including Hatch-Waxman disputes and inter partes review (IPR) proceedings. A seasoned trial lawyer and Ph.D. chemist, Gregory guides pharmaceutical, biotechnology and medical device companies in complex patent litigation and helps clients secure value by providing strategic IP counseling and due diligence advice.
Gregory’s work includes protecting innovative prescription drugs and biologics across key therapeutic areas, defending high-value patents and challenging competitor claims. Throughout his career, he has secured landmark decisions that have shaped patent law in the life sciences industry.
Gregory is widely regarded as one of the nation’s leading lawyers in his field. He has been consistently recognized as a “Life Sciences Star” by LMG Life Sciences, an “IP Star” by Managing IP and “Patent Star” by IAM Patent 1000, which ranks him among the world’s leading patent professionals. Gregory has also been repeatedly ranked as an IP leader by Chambers USA, where clients praise him as an [an] “outstanding attorney with first chair litigation capability, expert-level technical insight and an ability to marry technical expertise with a strategic view.”
Education
- Fordham University School of Law, J.D.
-
Northwestern University, Ph.D.
Organic Chemistry
- University of Michigan, B.A.
Admissions & Qualifications
- Illinois
- New York
- District of Columbia
Memberships
New Jersey Intellectual Property Owners Association
New York Intellectual Property Law Association
The Richard Linn American Inn of Court
Awards & Recognition
Chambers USA New York Intellectual Property: Patent 2021-2025
Managing Intellectual Property IP STARS, Patent Star, 2016-2025
IAM Patent 1000 The World’s Leading Patent Professionals, 2020-2025
LMG Life Sciences, Life Sciences Star, 2017-2024
Crain’s Chicago Business Notable Gen X Leaders in Law, 2019
Matters
Representative Matters*
- Lead counsel for a pharmaceutical company in Hatch-Waxman patent infringement litigation to protect clients’ prescription digestive drug. Obtained consent judgments with injunctions against all defendants. (D. Del.)
- Represented a multinational pharmaceutical company and a conglomerate corporation in patent infringement litigation filed by a US-based global manufacturer relating to the pharmaceutical company’s prescription asthma product. Achieved a complete victory whereby the asserted patents were invalidated in parallel IPRs and the complaint was dismissed with prejudice. (PTAB) (N.D. Ill.)
- Lead counsel for a pharmaceutical company in IPR proceeding where an opposing pharmaceutical company challenged client’s patent related to peptide therapeutics for the treatment of gastrointestinal disorders obtaining an order terminating the proceedings. (PTAB)
- Co-lead counsel for a multinational pharmaceutical company in IPR action against a Canadian pharmaceutical company who was seeking to challenge a patent protecting client’s prescription product. Obtained a win whereby the institution of the IPR proceeding was denied. (PTAB)
- Represented a Swiss pharmaceutical company and a biopharmaceutical company in parallel IPRs and Hatch-Waxman patent infringement litigation to protect clients’ prescription rosacea drug. Co-led team that obtained IPR win after final written decision that was the first-ever successful defense of an Orange Book-listed patent in an IPR review. Obtained consent judgments with injunctions against all defendants. (PTAB) (D. Del.)
- Represented a global healthcare company in Hatch-Waxman patent infringement litigation to protect client’s prescription digestive drug. Obtained a bench trial verdict at the close of evidence finding infringement and upholding the validity of the patents. Obtained consent judgments with injunctions against all defendants. (D. Del.)
- Represented an American pharmaceutical company in patent infringement litigation brought by a biopharmaceutical company involving client's humanized antibody drug, obtaining a dismissal of all claims. (D. Del.)
- Represented a pharmaceutical company and a Danish international pharmaceutical company in Hatch-Waxman patent infringement litigation to protect clients’ prescription digestive drug. Obtained consent judgments with injunctions against all defendants after bench trial. (D. Del.)
*Aforementioned matters handled at prior firm